focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.00
Bid: 33.00
Ask: 35.00
Change: -3.25 (-8.72%)
Spread: 2.00 (6.061%)
Open: 37.50
High: 37.50
Low: 33.50
Prev. Close: 37.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum shares slump on widened loss and funding talks

Tue, 12th Mar 2024 15:23

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Shares in the Cambridge, England-based pharmaceutical company were down 24% to 26.51 pence in London on Tuesday afternoon.

Sareum said it will publish its result the six months ended December 31 in the week beginning March 25.

It expects to report an operating loss of GBP2.5 million, widening from GBP1.7 million a year earlier.

The company explained that this reflects "the cost of continued and additional investment into clinical research conducted during the period for the furtherance of its SDC-1801 autoimmune disease programme."

It also updated markets on its equity prepayment facility with RiverFort Global Opportunities PCC Ltd.

Sareum has drawn GBP2.3 million to date from two prepayment deposits and the company currently has an outstanding balance of approximately GBP1.3 million under the facility.

Any remaining balances are not due for repayment until the maturity date in August 2025, by which all balances are expected to be settled through the issuance of placing shares.

Previously it has been announced that the facility included a committed third tranche prepayment deposit of GBP300,000.

However, it noted that "due to downward pressure on the company's share price", Sareum has been unable to draw down the third prepayment under the facility.

The company explained that it is now in discussions to assess alternative funding arrangements and has taken steps to preserve its immediate capital utilisation.

It added that, providing alternative funding is secured, the board remains confident that it is on course to deliver topline Phase 1a results in the second quarter of 2024.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities PCC Ltd. Issue is in line with facility announced in August. Says facility has an outstanding balance of GBP220,000.

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 11:20

Sareum hails safety profile for SDC-1801 after phase 1 trial

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.